Top 7 Antibody Engineering Platforms for 2026

Key Takeaways

• Affinity is the property teams optimize first and rarely the one that kills a candidate later.

• ConvergeAB leads this list because it optimizes multiple antibody properties in one environment rather than sequentially.

• Antibody engineering is a trade-off surface, so improving one property usually costs another unless both are modelled together.

• Platforms differ mainly in where they sit: sequence design, library discovery, laboratory testing, or the loop connecting them.

• Programmes lose the most time to developability failures discovered after months of optimization.

A campaign produces a binder with picomolar affinity in four months. It aggregates at the concentrations a subcutaneous formulation requires, expresses at a fraction of the titre manufacturing needs, and shows enough polyspecificity to raise questions nobody wants raised at that stage. The affinity was never the problem.

Antibody engineering is a multi-property optimization exercise disguised as a search for the tightest binder. Affinity, stability, expression, solubility, immunogenicity, specificity, and half-life all matter, they interact, and improving one commonly degrades another. Any platform that optimizes them one at a time is walking a path where the ground moves behind it.

The 7 Platforms

1. Converge Bio

Converge Bio approaches antibody engineering as a multi-property problem from the outset. Built on biological foundation models trained on the languages of DNA, RNA, and proteins, it generates and optimizes antibody sequences while accounting for the properties that decide developability rather than treating them as a downstream filter applied to whatever the affinity campaign produced.

The practical effect is on the order of the work. Where a sequential process improves binding and then discovers an aggregation liability, a model that represents both can propose sequences where the trade-off has already been navigated. Candidates arriving at experimental validation are therefore prioritized on more than one axis, which changes what gets tested rather than only how quickly it gets tested.

The environment matters as much as the models. Computational researchers and experimental biologists work on the same data in one place rather than exchanging spreadsheets across a boundary where context is lost, and results feed back into subsequent design rather than accumulating in a folder. For teams running several programmes, that continuity means each campaign starts with more than the last one did, which is the compounding advantage in-house platforms are built to capture.

What it contributes:

• Generative design of antibody sequences from biological foundation models

• Simultaneous optimization across affinity, stability, expression, and developability properties

• In-silico screening and prioritization before experimental resource is committed

• Humanization and liability reduction handled alongside binding rather than after it

• One environment shared by computational and experimental teams

• Experimental results feeding back into subsequent design cycles

2. AbCellera

AbCellera built its reputation on interrogating natural immune responses at very high throughput, screening large numbers of single antibody-secreting cells to find binders that immune systems have already refined against a target.

Nature produces functional, well-behaved antibodies, and starting from that pool rather than from a synthetic library avoids a class of problems by construction. The platform is oriented toward discovery from biological sources and partnership-based programmes, so organizations wanting design capability deployed inside their own team are addressing a different requirement.

What it contributes:

• High-throughput screening of natural antibody repertoires

• Single-cell interrogation of immune responses against a target

• Large-scale characterization of binder candidates

3. OmniAb

OmniAb develops transgenic animal platforms engineered to produce human-sequence antibodies, giving discovery campaigns access to repertoires shaped by in vivo maturation across several species backgrounds.

The diversity available through that route is difficult to reproduce synthetically, and antibodies emerging from it have already passed through biological selection for stability and expression. It supplies the discovery starting point rather than the computational optimization applied afterwards, which is why it commonly sits upstream of an engineering platform.

What it contributes:

• Transgenic platforms producing human-sequence antibodies

• Repertoire diversity from in vivo maturation

• Access to multiple species backgrounds for difficult targets

4. BigHat Biosciences

BigHat pairs machine learning with its own synthetic biology laboratory so that model predictions are tested rapidly and the results retrain the models, treating design and experiment as one cycle rather than two handoffs.

Its stated focus on properties beyond affinity, including stability and developability characteristics, reflects the same recognition that late-stage failures come from elsewhere. The integrated wet lab is central to the model, which suits partnership arrangements more than deployment inside another organization’s own workflow.

What it contributes:

• Machine learning guidance over antibody sequence design

• An integrated laboratory closing the design and test loop quickly

• Optimization targeting developability alongside binding

5. LabGenius

LabGenius applies automated experimentation to antibody engineering, using robotics and machine learning to run evolutionary cycles in which each round of candidates is informed by the measured performance of the last.

The approach suits complex molecular formats where intuition offers little guidance and the search space is too large to explore by hand. Throughput is bounded by laboratory capacity rather than by compute, which shapes how many properties can realistically be examined in parallel.

What it contributes:

• Automated design, build, and test cycles for antibody candidates

• Machine learning applied to experimental measurements

• Exploration of complex and multi-specific formats

6. Adaptyv Bio

Adaptyv Bio provides rapid protein expression and characterization as a service, letting computational teams submit designed sequences and receive experimental binding and biophysical data without operating a laboratory themselves.

That fills a practical gap for organizations whose design capability outpaces their access to testing capacity. It validates designs rather than generating them, so it complements a design platform rather than substituting for one.

What it contributes:

• Rapid expression and testing of designed protein sequences

• Binding and biophysical characterization data returned to design teams

• Experimental capacity without laboratory infrastructure

7. Twist Bioscience

Twist Bioscience manufactures synthetic DNA at scale and supplies antibody libraries built on that capability, providing the physical substrate that discovery and engineering campaigns depend on.

Precisely designed synthetic libraries allow control over diversity that natural sources do not offer, which matters for difficult epitopes and unusual formats. It is infrastructure for the field rather than an optimization platform, and campaigns using it still require design and selection capability elsewhere.

What it contributes:

• High-fidelity synthetic DNA at scale

• Antibody libraries with controlled, designed diversity

• Gene synthesis supporting variant construction

Frequently Asked Questions

What is antibody engineering?

Antibody engineering is the deliberate modification of antibody sequences to improve therapeutic properties, covering affinity, stability, expression, specificity, immunogenicity, and formulation behaviour. It differs from discovery, which finds an initial binder, and it is where most of the work between a hit and a candidate takes place.

Why is affinity not the main challenge?

Because affinity maturation is well understood and the properties that cause late failures are not. Candidates are more often abandoned for aggregation, poor expression, polyreactivity, or immunogenicity risk than for insufficient binding, and those properties interact with each other and with affinity itself.

Can antibody properties be predicted computationally?

Increasingly, though accuracy varies by property. Stability and expression prediction have improved substantially, while immunogenicity remains harder. The realistic role of computation is prioritizing which candidates deserve experimental resource rather than eliminating the need to test them.